FDA Approved: IMATINIB MESYLATE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approved a supplemental ANDA for Imatinib Mesylate (Chartwell RX, LLC), enabling marketing of a generic version of the cancer drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor
• Hypereosinophilic Syndrome
• Systemic Mastocytosis

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

SUPPL AP for IMATINIB MESYLATE (IMATINIB MESYLATE)